Figure 6.

Fn14-TRAIL · pSBC21 treatment reduces early activated CD4⁺ IL-17-producing cells and CD8⁺ cells in the CNS of MOG-challenged mice. MOG-challenged mice, treated with either pSBC21 vector only or Fn14-TRAIL · pSBC21 (three mice per group), or naïve mice (no MOG challenge), were sacrificed on day 7 after challenge, and flow cytometry was performed on mononuclear cells isolated from their brains or pooled spinal cords/cerebellums/brain stems. Live lymphocytes were gated based on forward and side scatter. A: Left: Early activated (CD69⁺) IL-17-producing cells, gated on CD4⁺ lymphocytes; right: depiction of percentage of CD4⁺CD69⁺ IL-17-producing cells. B: Left: CD8⁺ cells, gating on live lymphocytes; right: depiction of percentage of CD8⁺ lymphocytes. The data shown are representative of three independent experiments.